https://www.selleckchem.com/pr....oducts/R788(Fostamat
The optimal approach to combine gemtuzumab-ozogamicin (GO) with various chemotherapy backbones and other newer agents safely remains to be determined. We performed a retrospective analysis of the safety and outcomes of adult patients with newly diagnosed acute myeloid leukemia (AML) treated with GO with intensified versus standard anthracycline doses (daunorubicin dose 90 mg/m vs 60 mg/m ) ± FLT3 inhibitors. The χ test and Mann-Whitney U test were used to compare categorical and continuous data. Survival estimates we
Curtir
Comentario
Compartilhar
